Pharma Equity (Denmark) Performance
| PEG Stock | 0.14 0.01 6.67% |
The company holds a Beta of 0.83, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Pharma Equity's returns are expected to increase less than the market. However, during the bear market, the loss of holding Pharma Equity is expected to be smaller as well. At this point, Pharma Equity Group has a negative expected return of -0.71%. Please make sure to check Pharma Equity's standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if Pharma Equity Group performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pharma Equity Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Pharma |
Pharma Equity Relative Risk vs. Return Landscape
If you would invest 24.00 in Pharma Equity Group on September 3, 2024 and sell it today you would lose (10.00) from holding Pharma Equity Group or give up 41.67% of portfolio value over 90 days. Pharma Equity Group is producing return of less than zero assuming 4.7554% volatility of returns over the 90 days investment horizon. Simply put, 42% of all stocks have less volatile historical return distribution than Pharma Equity, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Pharma Equity Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharma Equity's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pharma Equity Group, and traders can use it to determine the average amount a Pharma Equity's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.15
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PEG |
Estimated Market Risk
| 4.76 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.71 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.15 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pharma Equity is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharma Equity by adding Pharma Equity to a well-diversified portfolio.
Things to note about Pharma Equity Group performance evaluation
Checking the ongoing alerts about Pharma Equity for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pharma Equity Group help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharma Equity Group generated a negative expected return over the last 90 days | |
| Pharma Equity Group has some characteristics of a very speculative penny stock | |
| Pharma Equity Group has high historical volatility and very poor performance |
- Analyzing Pharma Equity's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharma Equity's stock is overvalued or undervalued compared to its peers.
- Examining Pharma Equity's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharma Equity's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharma Equity's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pharma Equity's stock. These opinions can provide insight into Pharma Equity's potential for growth and whether the stock is currently undervalued or overvalued.